Stocklytics score rationale: value 75, quality 40, growth 25.
Financials
2017
2018
2019
2020
2021
2022
2023
2024
2025
10500000000
9777000000
7777000000
6532000000
6304000000
6174000000
6263000000
6403000000
6216000000
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis…
Forecast
Consensus Hold from 5 analysts. Average price target $11.00, -20.4% versus the current price. Low $8.00. High $14.00.
Analysts have an average 12-month price target of $11.00 for Organon & (OGN), 20.3% below the current price of $13.80. Of 5 analysts covering the stock, 0 rate it Buy or Strong Buy, 4 Hold, and 1 Sell or Strong Sell, giving a consensus of Hold.
Forecasts are third-party estimates and often wrong. They are not investment advice.
OGN price target
12-month price target
Low
$8.00
Average
$11.00
High
$14.00
The average is 20.3% below the current price of $13.80.
Is Organon & a buy or sell?
Of 5 analysts, 0 rate Organon & Buy or Strong Buy, 4 Hold, and 1 Sell or Strong Sell. The consensus label is Hold. That split is not a recommendation.
The Stocklytics Score for OGN is 47 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
OGN forecast FAQs
What is the OGN price target?
$11.00 average, with a published range of $8.00 to $14.00.
Is Organon & a buy or sell?
The consensus is Hold from 5 analysts. This is not a recommendation.
What is the Organon & stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is $3.35. The average revenue estimate is $6.13 billion.
What will OGN be worth in 2030?
No reliable forecast exists that far out.
When is Organon &'s next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.